CADL
Candel Therapeutics, Inc.
There isn't enough reported data to score CADL yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CADL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Unavailable | |
| Unavailable |
CADL's revenue is currently stable, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CADL PE Valuation
CADL has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CADL Forward outlook
There aren't enough analyst estimates for CADL to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CADL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.49 | -$0.93 |
| Q2 2026 | -$1.42 | -$0.74 |
| Q1 2026 | -$0.99 | +$0.34 |
| Q4 2025 | -$0.72 | +$1.02 |
| Q3 2025 | -$0.56 | +$1.18 |
| Q2 2025 | -$0.68 | +$1.02 |
| Q1 2025 | -$1.33 | -$0.04 |
| Q4 2024 | -$1.74 | -$0.43 |
CADL lost $1.49 per share over the past year, and its loss has widened in each of the last four quarters.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CADL on earnings quality, reporting a profit while its opponent remains loss making.
CADL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $31K | 0% |
| Q3 2022 | $31K | 0% |
| Q2 2022 | $31K | 0% |
| Q1 2022 | $31K | 0% |
| Q4 2021 | $31K | 0% |
| Q3 2021 | $31K | 0% |
| Q2 2021 | $31K | 0% |
| Q1 2021 | $31K | 0% |
LLY has the stronger quarterly revenue trend. Revenue is flat for CADL versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2022 | -26132% | -1165 points |
| Q3 2022 | -28648% | -2748 points |
| Q2 2022 | -28235% | -11136 points |
| Q1 2022 | -28987% | -13965 points |
| Q4 2021 | -24968% | -5210 points |
| Q3 2021 | -25900% | -17032 points |
| Q2 2021 | -17100% | -8652 points |
| Q1 2021 | -15023% | -7545 points |
CADL's operating margin was −26132% last quarter, down 1165 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
CADL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.3M | -$12.9M |
| Q2 2026 | -$17.3M | -$8.3M |
| Q1 2026 | -$18.7M | -$10.1M |
| Q4 2025 | -$11M | -$5.2M |
| Q3 2025 | -$10.4M | -$3.8M |
| Q2 2025 | -$8.9M | -$2.7M |
| Q1 2025 | -$8.6M | -$174K |
| Q4 2024 | -$5.8M | +$1.7M |
CADL has burned cash in almost every quarter: −$70M over the past year, against −$34M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CADL on cash generation, producing positive trailing cash flow while its opponent burns cash.
CADL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.4% | +3.3M shares |
| 1 year | +50% | +25.9M shares |
| 3 years | +168% | +48.5M shares |
| 5 years | +566% | +65.8M shares |
CADL has 77M diluted shares, up 50% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CADL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CADL Net Leverage
CADL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CADL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.5 | Neutral |
| Stochastic | 12.5 | Oversold |
CADL's weekly RSI is 44 (neutral) and its Stochastic is 13 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CADL PE vs Healthcare Sector
CADL has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CADL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.10 | 7.8% below |
| 20 week MA | $10.2 | 18% below |
| 50 week MA | $7.93 | 5.8% above |
| 100 week MA | $7.10 | 18% above |
| 200 week MA | $5.18 | 62% above |
CADL has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 62% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CADL on trend strength, trading above more of its moving averages.
CADL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $7.59 | $8.40 | +11% |
| 2022 | $8.40 | $1.52 | -82% |
| 2023 | $1.52 | $1.47 | -3.3% |
| 2024 | $1.47 | $8.87 | +503% |
| 2025 | $8.87 | $6.01 | -32% |
| 2026 YTD | $6.01 | $8.39 | +40% |
CADL has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.